Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results
Date:11/11/2010

h and profitability, while positioning China Pharma to benefit from China's unprecedented $124 billion healthcare reform program," said Ms. Li.  "We believe our future success will be defined by our high-quality manufacturing facilities, strong distribution relationships, and commercialization expertise."

Pipeline UpdateAs of September 30, 2010, China Pharma had nine pipeline drugs in different stages of registration process, including three that have passed China State Food and Drug Administration ("SFDA") technical analysis and entered clinical trials.

  • The Company has completed clinical trials of Candesartan, a front-line drug therapy for the treatment of hypertension. The Company has completed all testing procedures and currently awaits final SFDA production approval.
  • The Company continues to receive positive feedback from patients in the clinical trial of Rosuvastatin, a generic form of Crestor. The majority of patients in the clinical trial have completed the treatment cycle and the trial is near completion.
  • The Company completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic in the third quarter of 2010.  Phase I of the clinical trials focused on the study of clinical pharmacology as well as the evaluation of safety on the human body, while observing tolerance and pharmacokinetics to provide support for dosage and drug delivery design. Phase II has commenced.

  • Conference CallThe Company will hold a conference call at 8:00 am EST on November 11, 2010 to discuss third quarter 2010 results.  Listeners may access the call by dialing 1-800-659-2056 or 1-617-614-2714 for international callers; access code: 56441223.  A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com.  A replay of the call will be accessible through November 18, 2010 by dialing 1-888-286-8010 or 1-617-80
    '/>"/>

    SOURCE China Pharma Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
    (Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
    (Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
    Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
    (Date:7/22/2014)... Robert E. Marc, Ph.D., director of research at the ... been named by the International Society of Eye Research ... Research Foundation,s 2014 Paul Kayser International Award in Retina ... scientist who has made a significant contribution to the ... being presented this week at the ISER Biennial Meeting ...
    (Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
    (Date:7/22/2014)... The 6th Latin American Conference on Lung Cancer (LALCA ... in Lima, Peru. , Lung Cancer is still the ... but worldwide. Building on the success of the previous ... national speakers will discuss the science and advances in ... malignancies worldwide and Latin America in particular. , With ...
    (Date:7/22/2014)... 2014 The Entertainment Industries Council, Inc. ... educational tools and recognition activities for thousands of entertainment ... treatment and recovery. On July 24, 2014, at 8pm, ... of these resources with a special mention of the ... treatment website at the end of the show. ...
    (Date:7/22/2014)... Doheny HealthDay Reporter TUESDAY, ... a minimally invasive procedure known as morcellation carries a risk ... the likelihood more clearly. Twenty-seven of every 10,000 women ... time of the procedure, researchers found, with the odds being ... performing a hysterectomy with morcellation use a power cutter to ...
    Breaking Medicine News(10 mins):Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3
    ... Health Care Budget Reform and Transparency Act of 2009 ... Government Employees, today, lauded the efforts of Congress in passing ... provided by the Department of Veterans Affairs. For more than ... VA funding process. AFGE applauds these members of Congress for ...
    ... will host "S,more to Love", a cocktail fundraiser on Friday, November ... benefit Birch Family Camp. , Celebrating its 20th year, the Birch ... the 5 boroughs of NYC, along with 200 volunteers for a ... located in the Hudson Valley. Throughout the year this community ...
    ... Health and Wellness Partners, Inc. (HWP), a wholly owned subsidiary ... line of nutraceutical products called Surge, www.feelthesurge.com ... world to develop and refine production of the product line. ... "We placed our first large production order with one of ...
    ... companies have been doing it for years. Why not ... thoughtful discussion in hospitals and as a way to ... secondary markets. One developer, North Carolina-based Oaks ... medical office buildings (MOBs). As such, the innovative developer ...
    ... in Cell Cultures and in Patients , PHILADELPHIA, ... to The Children,s Hospital of Philadelphia Research Institute will ... HIV infection -- a unique class of drugs focused ... AIDS. , Unlike many current HIV treatments, which ...
    ... University of Rochester Medical Center demonstrates that, for certain ... may be a cost effective treatment. The implantable ... for individuals with drug resistant hypertension. The ... Journal of Clinical Hypertension used data from ...
    Cached Medicine News:Health News:VA Funding Reform Bill Clears Congress 2Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:Health and Wellness Partners, Inc., Says to America 'Feel the Surge' 2Health News:Health and Wellness Partners, Inc., Says to America 'Feel the Surge' 3Health News:Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:Cost effectiveness of blood pressure device evaluated 2Health News:Cost effectiveness of blood pressure device evaluated 3
    Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
    Hardy pituitary spoon, bayonet, malleable....
    ... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
    ... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
    Medicine Products: